A
Alcista
Alcista · 25%PGEN
$2.28
Precio del escenario
$6.145
+0.107 (+1.74%)Al cierre
Loading chart…
- Máximo
- 6.220
- Apertura
- 6.010
- Precio medio ponderado por volumen
- 6.11
- Volumen
- 3.79M
- Capitalización
- 381.15M
- Mínimo
- 5.960
- Importe
- 23.15M
- EV/EBITDA, TTM
- 12.30
Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Análisis de IA of Precigen Inc (PGEN)
ComprarPrecigen Inc (PGEN) is a good buy right now due to its recent strong earnings performance, with Q2 2026 showing a net income of $20.1 million and an EPS of $0.05, which significantly exceeded expectations. Additionally, the stock is currently priced at $6.19, with analysts projecting a price target of $12, indicating a potential upside of approximately 93%.
Métricas de valoración
El PER previsto actual de Precigen Inc (PGEN) es 16.89, frente a su media de 5 años de 9.46.
Escenarios de precio de Alphio AI para PGEN
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con PGEN en cartera
Cronología de eventos
Noticias
6.009-25NASDAQ.COMB. Riley Securities Initiates Buy Rating on Precigen
6.009-25stocktwitsB. Riley Initiates Coverage of PGEN with Buy Rating
9.009-21PRnewswirePrecigen Receives FDA Platform Technology Designation for AdenoVerse
9.009-21NewsfilterPrecigen Receives FDA Platform Technology Designation
9.508-05seekingalphaPrecigen Reports 145% Revenue Growth in Q2 2026 Driven by PAPZIMEOS
Preguntas frecuentes sobre PGEN, respondidas por Alphio AI
Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Precigen Inc (PGEN) is a good buy right now due to its recent strong earnings performance, with Q2 2026 showing a net income of $20.1 million and an EPS of $0.05, which significantly exceeded expectations. Additionally, the stock is currently priced at $6.19, with analysts projecting a price target of $12, indicating a potential upside of approximately 93%.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.